August 2024 in “International Journal of Molecular Sciences” Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
April 2024 in “International journal of molecular sciences” Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.
April 2024 in “International journal of molecular sciences” Light-based treatment, Photobiomodulation, shows promise for non-invasive skin therapy with few side effects.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
February 2024 in “International journal of molecular sciences” Type 3 Innate Lymphoid Cells help maintain skin health and balance, and are involved in skin diseases and healing.
December 2023 in “Regenerative therapy” miRNA-based therapies show promise for treating skin diseases, including hair loss, in animals.
September 2023 in “JEADV Clinical Practice” People with common hair loss conditions may have a higher risk of heart disease and related health issues.
July 2023 in “Stem Cells Translational Medicine” Mesenchymal Stem/Stromal Cells (MSCs) help in wound healing and tissue regeneration, but can also contribute to tumor growth. They show promise in treating chronic wounds and certain burns, but their full healing mechanisms and potential challenges need further exploration.
Thermal spring waters and their microbes could be good for skin health and treating some skin conditions in skincare products.
February 2026 in “Stem Cell Research & Therapy” Stem cell therapies show promise for hair regrowth in alopecia areata but need more research for safety and effectiveness.
Scalp microbiome in young women is mainly affected by sensitivity, sebum, and lifestyle.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
September 2025 in “International Journal of Molecular Sciences” International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.
September 2025 in “Diseases” Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.
Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
May 2024 in “Russian Journal of Allergy” Alopecia areata often occurs with atopic diseases, especially in children.
February 2024 in “World journal of stem cells” Adipose-derived stem cells can help repair and improve eye tissues and appearance.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
May 2023 in “International Journal of Molecular Sciences” Mesenchymal stem cells could help treat radiation-induced bladder damage but more research is needed to overcome current limitations.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
July 2019 in “Dermatology practical & conceptual” The study found that alopecia areata is strongly linked to autoimmune diseases and may indicate a genetic predisposition to such conditions.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
50 citations
,
December 2005 in “European Journal of Immunology” RXRα is crucial for proper immune response and links diet to immune function.
15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
4 citations
,
January 2011 in “Journal of UOEH” Autoimmune hair loss may be linked to increased Th1 and Th17 cells and decreased Th2 cells.
2 citations
,
November 2004 in “Blood” RXRa is crucial for Th2 immune cell development and may link nutrition to immune health.
April 2019 in “Journal of Investigative Dermatology” Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.